Abstract

Although the translation of experimental molecular MR imaging agents is highly compelling, it is substantially more complex than the translation of radiolabeled imaging agents. The prognostic value, safety, and cost-effectiveness of molecular MR imaging for the detection of plaque inflammation will need to be demonstrated and will require a robust and collaborative effort among basic scientists, clinicians, epidemiologists, and industry. The well-conducted and valuable study reported by Amirbekian et al in this issue of Radiology adds further momentum to this important endeavor.